WALTHAM, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today the appointment of Dr. Willard H. Dere, to its Board of Directors. Dr. Dere was formerly at Amgen, where he led the development program of Prolia.
"We are very pleased to welcome Dr. Willard Dere to the Radius Health Board," said President and CEO, Robert Ward of Radius Health. "Dr. Dere's deep expertise in the area of endocrinology and metabolic diseases and range of scientific, research and regulatory experiences within the healthcare industry will provide immense insight as we continue to advance the development of our lead investigational drug candidate abaloparatide."
Dr. Willard Dere is Executive Director of Personalized Health at the University of Utah Health Sciences Center, and a member of the Department of Medicine and Division of Endocrinology and Metabolism. Prior to re-joining academia, Dr. Dere was in the biopharmaceutical industry for 25 years. He started working at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. At Eli Lilly, he led the development of Evista and Forteo. He joined Amgen in 2003 where he held multiple roles including head of global development, international medical, and both corporate and international chief medical officer. At Amgen, he led the development program of Prolia and several other programs. Dr. Dere retired from Amgen at the end of October 2014.
Dr. Dere received a B.A. degree in Zoology and History and an M.D. degree from the University of California, Davis. He has published over 50 articles; wrote and co-edited a primary care textbook; was awarded the 2008 transformational leadership award from UC Davis; and is a fellow in the American College of Physicians.
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com
CONTACT: Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Barbara.Ryan@fticonsulting.com Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612 Kimberly.Ha@fticonsulting.comSource:Radius Health